MUCOSOLVAN*SYR 200ML 15MG/5ML

MUCOSOLVAN 15 mg/5 ml forest fruit flavour syrup
Ambroxol

What it is and what it is used for
Mucosolvan contains ambroxol, an active ingredient that works by dissolving and facilitating the elimination of phlegm. Mucosolvan is used in adults and children over 2 years of age for the treatment of secretions in acute and chronic bronchial and lung diseases (i.e., in the presence of a cough and difficulty expelling phlegm from the bronchi due to increased or thickened phlegm).

What you need to know before taking the medicine
Consult your doctor or pharmacist before using Mucosolvan:
- if you/your child has/have had stomach and/or intestinal lesions (peptic ulcer).

Cases of severe skin reactions associated with ambroxol administration have been reported. If you develop a skin rash (including lesions of mucous membranes such as the mouth, throat, nose, eyes, genitals), stop taking Mucosolvan and seek immediate medical attention.
Such reactions could be symptoms of serious skin conditions characterized by skin peeling and severe toxic skin reaction (Stevens-Johnson syndrome and Toxic Epidermal Necrolysis).

Furthermore, in the initial phase of Stevens-Johnson syndrome or Toxic Epidermal Necrolysis (TEN), you/your child may experience non-specific symptoms similar to those of the flu, such as fever, chills, runny nose (rhinitis), cough, and sore throat. Due to these misleading symptoms, it is possible that symptomatic treatment with cough and cold therapy may be restarted.

Children
Do not give this medicine to children under 2 years of age. Mucolytics can induce bronchial obstruction in children under 2 years of age. This is because the drainage capacity of bronchial mucus is limited in this age group due to the physiological characteristics of the respiratory tract.

Warnings and precautions
Tell your doctor or pharmacist if you/your child is taking, has recently taken, or might take any other medicines. In particular, following ambroxol administration, concentrations of antibiotics (amoxicillin, cefuroxime, erythromycin) in bronchopulmonary secretions and saliva are increased.

Possible side effects
December 2022